Share This Page
Drug Sales Trends for trintellix
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for trintellix
Drug Name | Revenues (USD) | Units | Year |
---|---|---|---|
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2021 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2020 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2019 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2018 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2017 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2016 |
TRINTELLIX | ⤷ Subscribe | ⤷ Subscribe | 2015 |
>Drug Name | >Revenues (USD) | >Units | >Year |
Trintellix Market Analysis and Financial Projection
Market Analysis and Sales Projections for Trintellix (Vortioxetine)
Overview of Trintellix
Trintellix, also known as vortioxetine, is an antidepressant medication approved for the treatment of major depressive disorder (MDD) in adults. It is classified as a serotonin modulator and stimulator (SMS) and has a unique mechanism of action compared to other antidepressants[3].
Current Market Performance
Global Market Size
As of 2024, the global vortioxetine market size is estimated to be USD 915.8 million. This figure is part of a broader trend where vortioxetine has established itself as a significant player in the antidepressant market[4].
Regional Performance
- North America: The North American market for vortioxetine generated USD 366.32 million in 2024, with a projected compound annual growth rate (CAGR) of 8.8% from 2024 to 2031[4].
- Europe: Europe accounts for more than 30% of the global revenue, with a market size of USD 274.74 million in 2024. The European market is expected to grow at a CAGR of 9.1% from 2024 to 2031, driven by robust pharmaceutical research and development[4].
- Asia Pacific: The Asia Pacific region holds around 23% of the global revenue, with a market size of USD 210.63 million in 2024. This region is expected to grow at a CAGR of 12.6% from 2024 to 2031, influenced by growing urbanization and lifestyle changes[4].
- Latin America and Middle East & Africa: These regions also contribute significantly, with Latin America holding around 5% of the global revenue and the Middle East & Africa holding around 2%. Both regions are expected to see growth, driven by increasing awareness of mental health[4].
Sales Performance of Trintellix
Revenue Growth
In 2023, Trintellix generated revenue of DKK 4,324 million (approximately USD 640 million), representing a growth of 1% (or 5% in constant exchange rates)[5].
Regional Sales
- United States: The U.S. market is a significant contributor to Trintellix sales, driven by factors such as price increases and changes in the payer mix. However, sales have been negatively impacted by declining demand and higher gross-to-net adjustments[5].
- Europe and International Markets: Trintellix has seen strong performance in Europe and other international markets, including Spain, Italy, and Japan, with revenue growth driven by increased demand and market share gains[2].
Challenges and Opportunities
Generic Erosion
One of the major challenges facing Trintellix is the potential for generic erosion. As patents expire for key products, including Trintellix, the entry of cheaper generics could result in sales erosion. For instance, Lundbeck/Takeda Pharmaceuticals’ Trintellix, which was the top-selling drug in the MDD market in 2019, faces patent expiries that could impact its sales[1].
Market Growth Drivers
Despite the challenges, several factors are expected to drive the growth of Trintellix:
- Unique Mechanism of Action: Vortioxetine's distinctive mode of action as a serotonin modulator and stimulator makes it appealing to both physicians and patients[3].
- Regulatory Approvals: Recent approvals, such as the approval for Alzheimer’s disease-associated agitation (AADAD) in the U.S. and Canada, have led to significant growth in claims data and long-term-care uptake[5].
- Market Demand: The growing prevalence of depression and anxiety, particularly in regions like the Asia Pacific, drives the demand for effective antidepressants like Trintellix[4].
Sales Projections
Short-Term Projections
For the short term, Trintellix is expected to continue its growth trajectory, albeit with some challenges from generic erosion. In 2024, the global vortioxetine market is projected to expand, with regional markets contributing significantly to this growth. For example, the European market is expected to grow at a CAGR of 9.1%, while the Asia Pacific market is expected to grow at a CAGR of 12.6% from 2024 to 2031[4].
Long-Term Projections
In the long term, the global vortioxetine market is expected to reach USD 1,853.9 million by 2031, growing at a CAGR of 10.60% from 2024 to 2031. This growth will be driven by continued technological progress, regulatory assistance, and increasing awareness of mental health issues globally[4].
Key Takeaways
- Global Market Size: The global vortioxetine market size is USD 915.8 million in 2024.
- Regional Growth: Europe and the Asia Pacific are key growth regions, driven by robust pharmaceutical research and growing urbanization.
- Challenges: Generic erosion and declining demand in some markets are significant challenges.
- Opportunities: Unique mechanism of action, regulatory approvals, and growing market demand are key drivers of growth.
- Long-Term Projections: The global vortioxetine market is expected to reach USD 1,853.9 million by 2031.
FAQs
What is Trintellix used for?
Trintellix, or vortioxetine, is used for the treatment of major depressive disorder (MDD) in adults. It is also approved for other conditions such as Alzheimer’s disease-associated agitation (AADAD) in some regions[3][5].
What are the common side effects of Trintellix?
Common side effects of vortioxetine include nausea, vomiting, constipation, and sexual dysfunction[3].
How does Trintellix differ from other antidepressants?
Trintellix has a unique mechanism of action as a serotonin modulator and stimulator (SMS), distinguishing it from other antidepressants[3].
What are the regional growth projections for Trintellix?
The European market is expected to grow at a CAGR of 9.1%, while the Asia Pacific market is expected to grow at a CAGR of 12.6% from 2024 to 2031[4].
What challenges does Trintellix face in the market?
Trintellix faces challenges such as generic erosion, declining demand in some markets, and higher gross-to-net adjustments[1][5].
Sources
- Clinical Trials Arena: Major depressive disorder market to reach $9.6bn across 8MM by 2029[1].
- Lundbeck: Q2 2024 Final Report[2].
- Expert Market Research: Vortioxetine (Trintellix) Manufacturing Plant Project Report 2024[3].
- Cognitive Market Research: Global Vortioxetine Market Report 2024[4].
- Lundbeck: Q4 2023 Corporate Release[5].
More… ↓